

Roberto Montero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3147595/publications.pdf>

Version: 2024-02-01

53
papers

1,434
citations

331670

21
h-index

330143

37
g-index

54
all docs

54
docs citations

54
times ranked

1827
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 827-839.	2.4	111
2	Tension-Free Vaginal Tape Versus Transobturator Suburethral Tape: Five-Year Follow-up Results of a Prospective, Randomised Trial. <i>European Urology</i> , 2010, 58, 671-677.	1.9	91
3	The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. <i>Tumor Biology</i> , 2013, 34, 571-576.	1.8	88
4	Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 290-296.	1.4	83
5	Update on urodynamic bladder dysfunctions after radical hysterectomy for cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 323-329.	4.4	68
6	A new type of absorbable barbed suture for use in laparoscopic myomectomy. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 117, 220-223.	2.3	65
7	Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?. <i>Gynecologic Oncology</i> , 2013, 128, 579-583.	1.4	60
8	Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. <i>Tumor Biology</i> , 2012, 33, 2117-2123.	1.8	54
9	Ten years of HPV vaccines: State of art and controversies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 65-72.	4.4	52
10	Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. <i>Medical Oncology</i> , 2017, 34, 164.	2.5	51
11	A critical review on HE4 performance in endometrial cancer: where are we now?. <i>Tumor Biology</i> , 2014, 35, 881-887.	1.8	46
12	Feasibility of the Use of Novel Matrix Hemostatic Sealant (FloSeal) to Achieve Hemostasis during Laparoscopic Excision of Endometrioma. <i>Journal of Minimally Invasive Gynecology</i> , 2009, 16, 153-156.	0.6	44
13	Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?. <i>Tumor Biology</i> , 2014, 35, 7009-7015.	1.8	42
14	The effects of giving patients verbal or written pre-operative information in gynecologic oncology surgery: a randomized study and the medical-legal point of view. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 177, 67-71.	1.1	41
15	Update on lymphadenectomy in early and advanced ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2008, 20, 34-39.	2.0	37
16	Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. <i>Tumor Biology</i> , 2015, 36, 4151-4156.	1.8	37
17	Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study. <i>Menopause</i> , 2020, 27, 43-49.	2.0	35
18	Ovarian cancer relapse: From the latest scientific evidence to the best practice. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 28-38.	4.4	31

#	ARTICLE	IF	CITATIONS
19	REM (Risk of Endometrial Malignancy): A Proposal for a New Scoring System to Evaluate Risk of Endometrial Malignancy. <i>Clinical Cancer Research</i> , 2013, 19, 5733-5739.	7.0	28
20	Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 170, 539-543.	1.1	25
21	Influence of pneumoperitoneum pressure on surgical field during robotic and laparoscopic surgery: a comparative study. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 865-868.	1.7	24
22	Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up. <i>International Urogynecology Journal</i> , 2013, 24, 789-794.	1.4	21
23	Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 9-18.	2.4	21
24	Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy. <i>Annals of Surgical Oncology</i> , 2015, 22, 2387-2394.	1.5	20
25	Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. <i>Gynecologic Oncology</i> , 2016, 143, 584-588.	1.4	20
26	An ultra-miniinvasive treatment for stress urinary incontinence in complicated older patients. <i>Maturitas</i> , 2010, 65, 292-295.	2.4	18
27	A gastrointestinal stromal tumor presenting as a pelvic mass: A case report. <i>Oncology Reports</i> , 2009, 21, 899-902.	2.6	17
28	Effectiveness of CO ₂ laser on urogenital syndrome in women with a previous gynecological neoplasia: a multicentric study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 590-595.	2.5	17
29	A randomized controlled trial comparing four versus six courses of adjuvant platinum-based chemotherapy in locally advanced cervical cancer patients previously treated with neo-adjuvant chemotherapy plus radical surgery. <i>Gynecologic Oncology</i> , 2015, 139, 433-438.	1.4	16
30	The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 696-702.	2.5	16
31	Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 768-771.	2.5	16
32	Does Extensive Upper Abdomen Surgery During Primary Cytoreduction Impact on Long-term Quality of Life?. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 442-447.	2.5	15
33	The use of novel hemostatic sealant (Tisseel®) in laparoscopic myomectomy: a caseâ€“control study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 2046-2053.	2.4	14
34	Antiangiogenics and immunotherapies in cervical cancer: an update and futureâ€™s view. <i>Medical Oncology</i> , 2017, 34, 115.	2.5	14
35	Internet Use and Access, Behavior, Cyberbullying, and Grooming: Results of an Investigative Whole City Survey of Adolescents. <i>Interactive Journal of Medical Research</i> , 2017, 6, e9.	1.4	13
36	Surgical treatment of rectovaginal endometriosis with extensive vaginal infiltration: results of a systematic three-step vagino-laparoscopic approach. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 173, 83-87.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Adjuvant chemotherapy after primary treatments for cervical cancer: a critical point of view and review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 431-439.	2.4	11
38	Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset. <i>Medical Oncology</i> , 2017, 34, 82.	2.5	11
39	Chemotherapy as Adjuvant Treatment for Intermediate-High Risk Early-Stage Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1418-1423.	2.5	7
40	Learning curves of a resident surgeon performing transobturator tape procedures for stress urinary incontinence. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 134, 345-349.	2.3	6
41	Implementing the Risk of Endometrial Malignancy Algorithm (REM) adding obesity as a predictive factor: Results of REM-B in a single-center survey. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 225, 51-56.	1.1	6
42	Aortic lymphadenectomy in cervical cancer: Anatomy, classification and technique. <i>Gynecologic Oncology</i> , 2007, 107, S30-S32.	1.4	5
43	Bladder function after laparoscopic nerve-sparing radical hysterectomy. <i>Gynecologic Oncology</i> , 2011, 120, 315.	1.4	5
44	Long-term follow-up of bulking agents for stress urinary incontinence in older patients. <i>Menopause</i> , 2018, 25, 663-667.	2.0	5
45	The role of human epididymis protein 4 as a biomarker in gynecologic malignancies. <i>Minerva Ginecologica</i> , 2019, 71, 36-43.	0.8	4
46	Sacral neuromodulation after stabilization of L2-S1 vertebrae with metallic fixation devices: is it feasible?. <i>International Urogynecology Journal</i> , 2011, 22, 373-375.	1.4	2
47	Suburethral sling in autoimmune patients: complications, quality of life, and success rate. <i>International Urogynecology Journal</i> , 2012, 23, 453-457.	1.4	2
48	Post-radical hysterectomy detrusor dysfunctions: is sacral neurostimulation a valid treatment strategy?. <i>Supportive Care in Cancer</i> , 2014, 22, 1153-1154.	2.2	2
49	The role of macroplastique implantation in the management of occult urinary stress incontinence. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 225, 124-128.	1.1	2
50	Pelvicâ€cutaneous fistula after retropubic vaginal tape placement. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 105, 178-179.	2.3	1
51	Real-time infrared thermography for ureter detection during hysterectomy. <i>Journal of Surgical Research</i> , 2012, 178, 539-544.	1.6	1
52	Anterior colporrhaphy plus insideâ€out tensionâ€free vaginal tape for associated stress urinary incontinence and cystocele: 10â€year follow up results. <i>Neurourology and Urodynamics</i> , 2018, 37, 1144-1151.	1.5	1
53	Tailoring parametrectomy for early cervical cancer (Stage IA-IIA FIGO): a review on surgical, oncologic outcome and sexual function. <i>Minerva Obstetrics and Gynecology</i> , 2021, 73, 149-159.	1.0	0